Women who attend breast cancer screening between ages 50-69 have a 40% reduced risk of dying from breast cancer. Regular screening is also associated with a 23% risk reduction, resulting in approximately eight deaths prevented per 1,000 women regularly attending screening.
A new large study finds that women who are diagnosed with breast cancer and have a family history of the disease face no worse of a prognosis after treatment than other women with breast cancer. Successful treatment for breast cancer is just as likely in young patients with a family history of breast cancer, as in those without.
A new study suggests that background parenchymal enhancement (BPE) on MRI scans may help tailor screening and management strategies to individual breast cancer risk. Women with elevated BPE levels were nine times more likely to be diagnosed with breast cancer, while mammographic density showed no significant relationship.
Researchers have discovered a crucial gene, DNMT1, that maintains breast and cancer stem cells. High levels of DNMT1 expression are associated with increased risk of breast cancer, particularly in women over 30. Restoration of the opposing ISL1 gene significantly reduces stem cell populations and cancer growth.
Research by Cancer Research UK has identified a link between high estrogen levels and an increased risk of male breast cancer. Men with the highest levels of oestrogen were two and a half times more likely to develop breast cancer.
Researchers at Women's College Hospital identified a new breast cancer gene, RECQL, strongly linked to the onset of breast cancer in two populations of Polish and French-Canadian women. The study found that specific mutations in the gene were associated with a high risk of developing breast cancer.
A new study by Brigham and Women's Hospital finds that breast conserving therapy was successful in over 90% of women who became eligible after treatment with chemotherapy. Despite this, 31% of those eligible chose mastectomy, highlighting the need for further exploration of patient and surgeon factors.
A study found that oophorectomy significantly reduced breast cancer death risk in women with a BRCA1 gene mutation. The procedure also showed promise in reducing all-cause mortality, particularly among estrogen receptor-negative breast cancer patients.
Analysis of two Women's Health Initiative clinical trials reveals a pattern of changing influences on breast cancer incidence over time, with estrogen plus progestin use linked to increased risk and estrogen alone showing reduced risk. The study suggests that ongoing influences after stopping hormone therapy require recalibration of br...
The 14th St. Gallen International Breast Cancer Consensus Conference highlighted the need to refine breast cancer classification and predict treatment responses. The conference recommendations will set the standard for breast cancer care for two years, taking into account variable resource limitations worldwide.
A new study by Women's College Hospital found that women with diabetes are more likely to be diagnosed with advanced stage breast cancer. The study analyzed data from over 38,000 women and found that those with diabetes were 14% more likely to present with Stage II or III breast cancer.
A study found that pathologists' diagnoses for breast biopsies have a high rate of disagreement, especially for cases of atypical hyperplasia and ductal carcinoma in situ. The researchers suggest that obtaining a second opinion for these cases could help reduce unnecessary treatment.
Women with very low breast tissue density experience shorter disease-free survival and overall life expectancies compared to those with high-density breasts. A six-year follow-up study of 270 breast cancer patients found that lower breast tissue density is an independent poor prognostic factor for breast cancer.
A family history of prostate cancer in first-degree relatives increases breast cancer risk by 14%, according to a study of 78,171 women. Women with both breast and prostate cancer histories face an almost 2-fold increase in breast cancer risk
A new analysis of a large national database found that breast cancer survivors have an increased risk of developing thyroid cancer, especially within five years of their diagnosis. Women who received radiation therapy for breast cancer were more likely to develop aggressive thyroid cancer, but with smaller tumors and fewer treatments.
Researchers developed a test to identify women with triple-negative breast cancer, a form of disease difficult to treat. The test assesses gene activity in breast cancer cells, finding those resembling adult stem cells are more likely to spread and recur.
A Mayo Clinic study found that US women's awareness of breast density varies significantly by race, ethnicity, household income, education level, and healthcare experiences. More than half of women reported having heard of breast density, but only 53% knew it was associated with cancer risk.
A new study published in Molecular Cancer Therapeutics shows that a low percentage of androgen-receptor-positive cells in triple-negative breast cancer cells can benefit from anti-androgen therapies. This finding may lead to a larger pool of patients eligible for targeted cancer therapy.
A worldwide study of 100,000 women has discovered two new genetic variants associated with an increased risk of breast cancer. The variants are specifically linked to the most common form of breast cancer, oestrogen receptor positive, providing important clues about its causes and potential leads for treatment discovery.
A new study reveals distinct methylation patterns in primary biopsy breast cancer cells, indicating better or worse prognosis. This epigenetic signature can stratify triple-negative breast cancers into two sub-groups, allowing for more precise disease management and potential improved outcomes.
A UTSW study reveals a strong correlation between low levels of beclin 1 and both triple-negative breast cancer incidence and poor prognosis. Patients with low beclin 1 activity had a 67% increased risk of dying from breast cancer compared to those with higher levels.
A new breast cancer risk prediction model developed by the Mayo Clinic has been shown to be more accurate than the current screening standard in predicting breast cancer risk. The model uses histologic features of biopsied breast tissue and individual patient demographic information, classifying breast cancer risk with a concordance st...
Researchers have discovered a novel breast cancer gene called BCL11A that drives the development and progression of triple-negative breast cancer. The study found that BCL11A is active in approximately eight out of ten patients with basal-like breast cancer, and its activity is associated with a more advanced grade of tumour.
The EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program found significant improvements in survival for men with breast cancer, but not as high as for women. The study revealed distinct biological characteristics of male breast cancer, including lower rates of hormonal therapy and breast-conserving surgery.
Research reveals that blocking androgen receptors can reduce the growth of estrogen-positive breast cancers and kill triple-negative breast cancer cells. Combining these drugs with HER2 or mTOR-targeting therapies shows promise for increased effectiveness in treating breast cancer.
The study found tamoxifen reduced breast cancer rates by around 30% and oestrogen receptor positive invasive cancer by 35%. After 20 years, the estimated risk of developing breast cancer was 8% in the tamoxifen group, compared to 12% in the placebo group.
Dr. Jane Holland's study identified the main driver of basal breast cancer's aggressiveness and targeted treatments to combat it. Her work aims to test inhibitors in human breast cancer tissue, potentially leading to new and effective treatments.
James Ingle, a renowned breast cancer expert at Mayo Clinic, has been awarded the 2014 William L. McGuire Memorial Lecture Award for his groundbreaking research on pharmacogenomics in breast cancer treatment. His work aims to develop personalized approaches to prevent breast cancer in high-risk women by identifying genetic biomarkers t...
A team of researchers has discovered a way to make triple-negative breast cancer cells susceptible to chemotherapy by inhibiting the HIF protein network. The study found that HIF inhibitors can decrease tumor size and prevent relapse in mice, offering new hope for treatment-resistant patients.
A Mayo Clinic-led study found that nearly 15% of triple-negative breast cancer patients have deleterious mutations in predisposition genes, including BRCA1 and BRCA2. This suggests a different origin for the disease compared to other forms of breast cancer.
A new breast cancer vaccine developed at Washington University School of Medicine has shown safety and preliminary evidence of biological efficacy in patients with metastatic breast cancer. The vaccine targets a protein called mammaglobin-A, found almost exclusively in breast tissue, and primes the immune system to attack tumor cells, ...
Women undergoing breast cancer surgery showed significant improvements in breast reconstruction processes of care after hospitals opened comprehensive breast centers. These centers enhanced patient care by assembling specialized practitioners for coordinated breast cancer care.
A study found that combining digital mammography with tomosynthesis screening is more effective in detecting breast cancer among women with dense breasts. This combined approach avoids false-positive results and unnecessary procedures, making it a cost-effective option.
A new study found that chest radiation in childhood cancer patients increases their risk of developing breast cancer later in life. Nearly 20% of female survivors who received chest radiation developed breast cancer by age 40 compared to 0.3% of those who did not receive radiation.
A long-term study of patients with HER2-positive breast cancer shows that adding trastuzumab to chemotherapy improves overall and disease-free survival by 37% and 40%, respectively. The regimen is now the standard of care for early stage HER2-positive breast cancer.
The European Society for Medical Oncology calls for high-quality research and clinical trials for advanced breast cancer. Key areas of focus include treatment strategies for patients with liver or lung metastases, HER2-positive disease, and men receiving aromatase inhibitors.
Research suggests that lactation may reduce the risk of estrogen receptor-negative and triple-negative breast cancers in African American women. Parous women had a higher chance of developing these aggressive subtypes if they never breastfed, particularly those with four or more births.
Researchers found that NSAID use reduces ERα positive breast cancer recurrence by 50% and extends patients' disease-free period by more than two years. The study suggests a new possibility for reducing breast cancer recurrence among overweight and obese postmenopausal women.
A new study led by researchers at UCSF analyzed the effect of two widely used osteoporosis drugs on breast cancer risk in post-menopausal women. The findings suggest that low estrogen levels, rather than the drugs themselves, may be protecting against breast cancer.
Researchers have identified three genetic changes linked to an increased risk of breast cancer in East Asian women. These findings provide new insights into the genetics and biology of breast cancer.
A new skin gel form of tamoxifen has been developed and tested on women with non-invasive breast cancer, reducing cancer cell growth while minimizing side effects. The gel application was found to be effective in reducing blood clot risk associated with oral tamoxifen, offering a safer treatment option.
A new imaging technique combining four approaches can distinguish between malignant and benign breast tumors with high accuracy, potentially avoiding unnecessary biopsies. The multiparameter PET-MRI method showed a 96% success rate in distinguishing malignant from benign tumors.
Researchers found that BPA increases breast cancer cell proliferation and diminishes the effect of treatments for inflammatory breast cancer cells. The study suggests a possible link between BPA exposure and treatment resistance in breast cancer patients.
Researchers analyzed the impact of mammography on breast cancer rates and found a significant decrease in late-stage diagnoses. The study attributed this decline to successful screening programs, which led to increased detection of early-stage cancers.
Two studies published in PLOS Medicine found a link between moles and increased breast cancer risk. Women with more moles were more likely to develop breast cancer, particularly postmenopausal women. The findings suggest that nevi may be affected by hormone levels, which could be used as a marker for breast cancer risk.
Scientists identified a new protein, hnRNPM, that plays a key role in reprogramming breast cancer cells to spread. Removing this protein significantly reduces the ability of breast cancer cells to metastasize to other organs.
A new study from the University of Michigan found that about 70% of women with breast cancer who underwent a double mastectomy had very low risk of developing cancer in their healthy breast. However, many of these women were driven by fear of recurrence rather than medical necessity.
A study of 2,290 women with breast cancer found that while many consider or undergo contralateral prophylactic mastectomy (CPM) to prevent cancer in the other breast, most do not have a clinically significant risk. The procedure is often associated with genetic testing, family history, and higher education.
A nationwide dataset analysis found that black women are 1.84 times more likely to be diagnosed with triple-negative breast cancer, a subtype with poorer prognosis. Asian/Pacific Islander women were also more likely to be diagnosed with HER2-overexpressing breast cancer.
A study led by Tufts University researchers reveals that SLUG transcription factor regulates stem cell function and determines breast cancer type, with potential implications for targeted therapies. The study found that SLUG-deficient mice exhibited defects in breast-cell differentiation and tumor formation.
A new study reveals that clarity during consultations and the capability of clinical facilities significantly impact women's decisions regarding breast cancer surgery. Findings also show that MRI exams ordered less frequently in Canada led to fewer unnecessary prophylactic mastectomies compared to the US.
A large study has found that a larger waist circumference is associated with an increased risk of postmenopausal breast cancer. However, when adjusting for body mass index (BMI), the association disappeared. The research suggests that maintaining a healthy weight, regardless of body shape, may be key to reducing breast cancer risk.
Researchers identified a new drug, AMPI-109, effective against triple-negative breast cancer by targeting the PTP4A3 oncogene. The study also provided molecular insights into the disease's biology.
Researchers at Dartmouth's Norris Cotton Cancer Center have compiled a review of genetic-based testing in breast cancer diagnosis and treatment. Genomic testing enables personalized therapy, increasing precision and success rates for patients.
A UK study found that approximately one third of women are at higher risk of developing breast cancer and may require more frequent mammograms. Women with dense breast tissue were 2.9-fold more likely to develop breast cancer, highlighting the importance of personalized screening frequency.
A study at Tufts University has identified the gene TAZ as a critical regulator of breast cell development and cancer. The research team found that TAZ helps to control whether breast cells behave like basal or luminal cells, which is important in understanding and treating certain types of aggressive breast cancer.
Researchers identified a key biological mechanism explaining why women with dense breast tissue are at greater risk of developing breast cancer. The study found that the JNK1 signaling pathway is activated to a greater extent in fibroblasts from high-density breast tissue, creating an inflammatory environment that drives tumor formation.
A Canadian study of 89,000 women aged 40-59 found that annual breast screening did not reduce mortality from breast cancer beyond physical examination or usual care. The study also revealed that 22% of screen-detected cancers were over-diagnosed, with one over-diagnosed cancer for every 424 women screened.
A recent study suggests that women with a BRCA gene mutation who undergo a double mastectomy have a significantly lower risk of death from breast cancer, with an estimated 48% reduction in mortality. This finding has implications for the treatment options available to young women with early-stage breast cancer and BRCA mutations.
The new guideline aims to reduce unnecessary re-excision rates by identifying optimal margin widths that minimize ipsilateral breast tumor recurrence. Wider margin widths do not significantly lower the risk, and the choice of radiation technique should not depend on margin width.